Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05559359




Registration number
NCT05559359
Ethics application status
Date submitted
26/09/2022
Date registered
29/09/2022
Date last updated
16/10/2024

Titles & IDs
Public title
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Secondary ID [1] 0 0
J2T-MC-KGBI
Secondary ID [2] 0 0
18265
Universal Trial Number (UTN)
Trial acronym
ADorable-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Eczema 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lebrikizumab
Treatment: Drugs - Placebo
Treatment: Drugs - Topical corticosteroid

Experimental: Lebrikizumab (Cohort 1) - Participants who are 6 years to \<18 years of age, 12 years to \<18 years of age who weigh \<40 kilogram (kg) or 6 years to \<12 years of age (may weigh =40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS).

Dosing will be based on weight.

Experimental: Lebrikizumab (Cohort 2) - Participants who are 6 months to \<6 years of age, 2 years to \<6 years of age or 6 months to \<2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS.

Dosing will be based on weight.

Placebo comparator: Placebo - Participants will receive placebo matching lebrikizumab by SC injections with a TCS.


Treatment: Drugs: Lebrikizumab
Administered SC

Treatment: Drugs: Placebo
Placebo given SC

Treatment: Drugs: Topical corticosteroid
Topical corticosteroid
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction =2 points from Baseline
Timepoint [1] 0 0
Baseline to Week 16
Primary outcome [2] 0 0
Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) =75% Reduction from Baseline in EASI Score
Timepoint [2] 0 0
Baseline to Week 16
Secondary outcome [1] 0 0
Percentage of Participants Achieving EASI-90, a =90% Reduction from Baseline in EASI Score
Timepoint [1] 0 0
Baseline to Week 16
Secondary outcome [2] 0 0
Percentage Change from Baseline in EASI Score
Timepoint [2] 0 0
Baseline, Week 16
Secondary outcome [3] 0 0
Percentage of Participants with a Pruritus Numeric Rating Score (NRS) of =4 points at Baseline Who Achieve a =4-point Reduction from Baseline
Timepoint [3] 0 0
Baseline to Week 16
Secondary outcome [4] 0 0
Percentage Change from Baseline in Pruritus NRS Score
Timepoint [4] 0 0
Baseline, Week 16
Secondary outcome [5] 0 0
Change from Baseline in Children Dermatology Life Quality Index (cDLQI)
Timepoint [5] 0 0
Baseline, Week 16
Secondary outcome [6] 0 0
Percentage of Participants with a Pruritus NRS Score of =4 points at Baseline Who Achieve Both EASI-75 and a =4-point Reduction in Pruritus NRS Score from Baseline
Timepoint [6] 0 0
Baseline to Week 1
Secondary outcome [7] 0 0
Mean Change from Baseline in Parent-Reported Itch Severity Measure (PRISM)
Timepoint [7] 0 0
Baseline, Week 16
Secondary outcome [8] 0 0
Change from Baseline in Body Surface Area (BSA)
Timepoint [8] 0 0
Baseline, Week 16
Secondary outcome [9] 0 0
Percentage Change from Baseline in Scoring Atopic Dermatitis (SCORAD)
Timepoint [9] 0 0
Baseline, Week 16
Secondary outcome [10] 0 0
Percentage of Participants Achieving EASI-50, a =50% Reduction from Baseline in EASI Score
Timepoint [10] 0 0
Baseline to Week 16
Secondary outcome [11] 0 0
Pharmacokinetics (PK): Average Serum Lebrikizumab Concentration
Timepoint [11] 0 0
Week 14
Secondary outcome [12] 0 0
Percentage of Participants with Positive Responses by the modified Subcutaneous Administration Assessment Questionnaire (mSQAAQ)
Timepoint [12] 0 0
Week 14

Eligibility
Key inclusion criteria
* Have a diagnosis of AD prior to screening as stated in the criteria by the American

Academy of Dermatology for at least:

* 12 months s if participants are =6 years of age, and
* 6 months if participants are 6 months to <6 years of age

* Have an EASI score =16 at the screening and baseline
* Have an IGA score =3 (scale of 0 to 4) at the screening and baseline
* Have =10% BSA of AD involvement at the screening and baseline.
Minimum age
6 Months
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Are currently enrolled or have participated within the last 8 weeks in a clinical study involving an investigational intervention or any other type of medical research judged not to be scientifically or medically compatible with this study.
* Treatment with the following prior to the baseline:
* An investigational drug within 8 weeks or less than 5 half-lives, whichever is longer.
* Dupilumab within 8 weeks. Note: The enrollment of participants with prior use of Dupilumab will be limited to <20%.
* Treatment with a topical investigational drug within 2 weeks prior to the baseline.
* Have received a Bacillus Calmette-Guerin vaccination or treatment within less than 4 weeks before randomization.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/10/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/09/2025
Actual
Sample size
Target
300
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 0 0
Cornerstone Dermatology - Coorparoo
Recruitment hospital [4] 0 0
Veracity Clinical Research - Woolloongabba
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4151 - Coorparoo
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
New Hampshire
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Argentina
State/province [18] 0 0
Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autónoma De Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Santa Fe
Country [21] 0 0
Brazil
State/province [21] 0 0
Rio Grande Do Sul
Country [22] 0 0
Brazil
State/province [22] 0 0
São Paulo
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio de Janeiro
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Czechia
State/province [26] 0 0
Brno-mesto
Country [27] 0 0
Czechia
State/province [27] 0 0
Praha 8
Country [28] 0 0
France
State/province [28] 0 0
Drôme
Country [29] 0 0
France
State/province [29] 0 0
Loire-Atlantique
Country [30] 0 0
France
State/province [30] 0 0
Midi-Pyrénées
Country [31] 0 0
Germany
State/province [31] 0 0
Hessen
Country [32] 0 0
Germany
State/province [32] 0 0
Niedersach
Country [33] 0 0
Germany
State/province [33] 0 0
Nordrhein-Westfalen
Country [34] 0 0
Germany
State/province [34] 0 0
Sachsen
Country [35] 0 0
Japan
State/province [35] 0 0
Aichi
Country [36] 0 0
Japan
State/province [36] 0 0
Hiroshima
Country [37] 0 0
Japan
State/province [37] 0 0
Hokkaido
Country [38] 0 0
Japan
State/province [38] 0 0
Kanagawa
Country [39] 0 0
Japan
State/province [39] 0 0
Nagano
Country [40] 0 0
Japan
State/province [40] 0 0
Osaka
Country [41] 0 0
Japan
State/province [41] 0 0
Saitama
Country [42] 0 0
Japan
State/province [42] 0 0
Tokyo
Country [43] 0 0
Japan
State/province [43] 0 0
Kyoto
Country [44] 0 0
Japan
State/province [44] 0 0
Okayama
Country [45] 0 0
Mexico
State/province [45] 0 0
Distrito Federal
Country [46] 0 0
Mexico
State/province [46] 0 0
Jalisco
Country [47] 0 0
Mexico
State/province [47] 0 0
Morelos
Country [48] 0 0
Mexico
State/province [48] 0 0
Nuevo León
Country [49] 0 0
Mexico
State/province [49] 0 0
Chihuahua
Country [50] 0 0
Mexico
State/province [50] 0 0
Veracruz
Country [51] 0 0
Poland
State/province [51] 0 0
Mazowieckie
Country [52] 0 0
Poland
State/province [52] 0 0
Malopolskie
Country [53] 0 0
Poland
State/province [53] 0 0
Pomorskie
Country [54] 0 0
Poland
State/province [54] 0 0
Lódzkie
Country [55] 0 0
Spain
State/province [55] 0 0
Barcelona [Barcelona]
Country [56] 0 0
Spain
State/province [56] 0 0
Las Palmas
Country [57] 0 0
Spain
State/province [57] 0 0
Madrid
Country [58] 0 0
Spain
State/province [58] 0 0
Navarra
Country [59] 0 0
Spain
State/province [59] 0 0
Pontevedra [Pontevedra]
Country [60] 0 0
Spain
State/province [60] 0 0
València
Country [61] 0 0
Taiwan
State/province [61] 0 0
Kaohsiung
Country [62] 0 0
Taiwan
State/province [62] 0 0
Taichung
Country [63] 0 0
Taiwan
State/province [63] 0 0
Taipei
Country [64] 0 0
Taiwan
State/province [64] 0 0
Hsinchu
Country [65] 0 0
Taiwan
State/province [65] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Dermira, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Trial website
https://clinicaltrials.gov/study/NCT05559359
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)
Address 0 0
Country 0 0
Phone 0 0
1-317-615-4559
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05559359